drugset / Trial / NCT01843621
A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children
Phase 1/2
Completed
7 enrolled
U.S. Army Medical Research and Development Command
GlaxoSmithKline · collab
NaSingle-groupOpen-labelPrevention
Summary
One year follow-up on immunogenicity and safety of a booster dose of DEN vaccine administered approx. 1 year following the second dose
Timeline
- Start
- 2005-02
- Primary completion
- 2005-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DEN vaccine F17 | Vaccine | — | Subcutaneous |